Navigation Links
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Date:9/6/2013

ALISO VIEJO, Calif., Sept. 6, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

The settlement agreement grants Wockhardt the right to begin selling a generic version of NUEDEXTA on July 30, 2026, or earlier under certain circumstances. The parties have also agreed to file a stipulation and order of dismissal with the United States District Court for the District of Delaware which will conclude this litigation with respect to Wockhardt. The settlement does not end Avanir's ongoing litigation against the other two ANDA filers.

In compliance with U.S. law, the settlement agreement will be submitted to the U.S. Federal Trade Commission and the Department of Justice where it is subject to review.

About NUEDEXTA
NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide, the ingredient active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA Important Safety Information
NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variet
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
2. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
3. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
4. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
5. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
6. Avanir Pharmaceuticals to Participate in Two Conferences in August
7. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
9. Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
10. Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results
11. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, Inc. ... today announced that the Food and Drug Administration ("FDA"), ... comments on RCP,s Investigational New Drug ("IND") application before ... in the US. Dr. Chris Chapman ... and comments on our IND. When we receive the ...
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Four studies highlighting late-breaking research advances in the treatment ... at the 50th Annual Meeting of the American Society of ... Results from a study examining the ability of ... the inner lining of blood vessels, in patients with sickle ...
... at ASH Annual Meeting- , , ... announced results of a randomized phase III study presented ... of Hematology. The study in adult patients with hematological ... syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma ...
Cached Medicine Technology:Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 2Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 3Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 4Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 5Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 6Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 7Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 8Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 9Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5
(Date:7/14/2014)... City, NJ (PRWEB) July 14, 2014 ... the established global leader in enterprise-class cloud management, ... collaboration platforms, today announced AvePoint software will be ... leading managed cloud specialist. , The ... Rackspace to offer the following AvePoint solutions to ...
(Date:7/14/2014)... 2014 Many diet plans often recommend eating ... the School of Public Health at the University of Alabama ... near-zero effect on weight loss. Now experts are suggesting that ... form of portion control to trigger measurable weight ... and controlling how much is consumed, simply by using a ...
(Date:7/14/2014)... Kenn Renner recently released a new video describing his ... the business on Austin Real Estate Investments . , ... Renner – is internationally recognized for his combined expertise on ... Investing in real estate is a great way for people ... career, while others like to do it as a hobby. ...
(Date:7/14/2014)... Seattle, WA (PRWEB) July 14, 2014 ... eat,' but what exactly does that mean?” This question ... and recently featured on Western Washington Medical Group’s blog ... with their mental health in mind . , According ... caffeinated beverages are placing themselves at a high risk ...
(Date:7/14/2014)... Milpitas, CA, and Washington DC (July 14, 2014) ... will be at Microsoft Worldwide Partner Conference 2014 (WPC) ... to showcase its award-winning information archiving and eDiscovery platforms ... 365, Windows servers, SharePoint, and Azure cloud network in ... “In the information archiving and legal discovery space for ...
Breaking Medicine News(10 mins):Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Drink With Your Mental Health in Mind, Advises an Article by Mental Health America Featured by Western Washington Medical Group 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 4Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 5
... academics have been awarded funds from a huge European ... of individual people which could lead to everyone ... genetic and physiological make-up. Under the system, doctors ... of an individual patient,s health needs and medical history ...
... Steven Reinberg HealthDay Reporter , SUNDAY, July 24 ... new anti-clotting drug, Eliquis, to dual antiplatelet therapy may result ... and stroke, a new study finds. A trial evaluating ... severe bleeding among those taking Eliquis (apixaban) became apparent. ...
... July 23 (HealthDay News) -- Swimming may be easy on ... The most common injury among those who practice the ... percent of competitive swimmers, said Dr. Scott A. Rodeo, co-chief ... Special Surgery in New York City, who recently spoke at ...
... News) -- The ability of dolphins to resist infection and ... the treatment of human wounds, a researcher suggests. , ... documented," Dr. Michael Zasloff, adjunct professor at Georgetown University Medical ... news release. "How does the dolphin not bleed ...
... study by researchers at Drexel University,s School of Public Health ... gateway to the use of injected drugs such as heroin, ... drugs. The study, published in the International Journal of ... initiation into the misuse of opioid drugs. Common factors identified ...
... Amanda Gardner HealthDay Reporter , THURSDAY, July 21 ... Internet on their smartphones tend to hold the devices closer ... to work harder than usual, new research shows. This ... smartphones -- could put added strain on people who already ...
Cached Medicine News:Health News:Computer program could 'revolutionize the world's health care' 2Health News:Computer program could 'revolutionize the world's health care' 3Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 2Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 3Health News:Common Swimming Injuries Often Avoidable 2Health News:Dolphins' Superior Ability to Heal May Help Humans 2Health News:Drexel study: Misuse of pain medication is pathway to high-risk behaviors 2Health News:Drexel study: Misuse of pain medication is pathway to high-risk behaviors 3Health News:Smartphones May Be Taxing Your Eyes 2Health News:Smartphones May Be Taxing Your Eyes 3
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Intermittent catheter - Ready-to-Use Sterile, Enclosed System...
... The VerifyNow (Ultegra) System is ... which measures platelet induced aggregation as ... system consists of an instrument, a ... assay device contains reagents based on ...
... The Model 700 Whole Blood/Optical Lumi-Aggregometer available ... This new Aggregometer measures platelet function on ... blood or optical density in plasma with ... method. The Model 700 Aggregometer also has ...
Medicine Products: